<DOC>
	<DOCNO>NCT00228605</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability OraVescent fentanyl potential treatment breakthrough pain episode patient chronic noncancer pain .</brief_summary>
	<brief_title>Evaluating Safety Tolerability OraVescent Fentanyl Opioid Tolerant Patients With Noncancer Related Breakthrough Pain</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Chronic pain diagnosis Opioid tolerant Has average 14 breakthrough pain episode per day Drug abuse history Cardiopulmonary disease Monoamine oxidase inhibitor ( MAOIs ) Expected surgery relieve pain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Pain</keyword>
	<keyword>Sudden Pain</keyword>
	<keyword>Flares</keyword>
	<keyword>noncancer</keyword>
	<keyword>low back pain</keyword>
	<keyword>neuropathic pain</keyword>
	<keyword>osteoarthritis pain</keyword>
	<keyword>migraine</keyword>
	<keyword>chronic headache</keyword>
	<keyword>diabetic peripheral neuropathy</keyword>
</DOC>